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Abstract
Background: Molecular mechanisms involved in the pathogenesis of severe Plasmodium falciparum
malaria (SM), are not yet fully understood. Both endothelin-1 (ET-1) and C-type natriuretic peptide
(CNP) are produced by vascular endothelium and act locally as paracrine regulators of vascular
tone, ET-1 being a potent vasoconstrictor and CNP having strong vasorelaxant properties.
Methods: Plasma levels of ET-1 and N-terminal fragments of CNP (NT-proCNP) were studied on
admission and after 24 hours of treatment, using enzyme-linked-immunosorbent-assay (ELISA)
technique, in Gabonese children with severe falciparum malaria (SM, n = 50), with uncomplicated
malaria (UM, n = 39) and healthy controls (HC, n = 25).
Results: Compared to HC, malaria patients had significantly higher plasma levels of ET-1 and
significantly lower levels of NT-proCNP (p < 0.001 and p < 0.024 respectively). Plasma levels of
NT-proCNP were additionally decreased in SM patients compared to HC (p = 0.034), whereas UM
was not significantly different to HC. In the SM group we found a trend towards lower ET-1 levels
compared to UM (p = 0.085).
Conclusion: In the present study, an imbalance between the vasoconstricitve and vasorelaxant
endothelium-derived substances ET-1 and CNP in the plasma of children with falciparum malaria is
demonstrated, presumably in favor of vasoconstrictive and pro-inflammatory effects. These results
may indicate involvement of ET-1 and CNP in malaria pathogenesis. Furthermore, results of lower
ET-1 and CNP levels in SM may reflect endothelial cell damage.
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Background
Malaria, beside HIV and tuberculosis, is still a major cause
of death in developing countries, accounting for 300 –
500 million clinical cases and more than one million
deaths per year [1]. Plasmodium falciparum may lead to
severe malaria (SM), a complex clinical syndrome with yet
incompletely understood pathomechanisms.
It has been shown that the endothelium is critically
involved in the development of severe malaria [2-4]. The
endothelial response to injury in acute inflammation can
be divided into two phases: an initial rapid endothelial
cell activation with recruitment of neutrophils, changes in
levels of nitric oxide (NO), endothelin-1 (ET-1) and C-
type natriuretic peptide (CNP) amongst others, and a
slower response that depends on new gene expression and
fundamental changes in cell surface characteristics [5].
Endothelins are regulators of vascular tone, amplifiers of
inflammatory response and are involved in normal cell
proliferation as well as repair and tissue development [6].
Endothelin-1 (ET-1) is a 21-amino acid vasoconstrictive
peptide [6]. It is synthesized by vascular endothelial cells
as well as neurons, astrocytes and other cells at low basal
levels and ET-1 tissue expression is up-regulated in
response to a variety of stress stimuli [6]. ET-1 can modu-
late the endothelial expression of adhesion molecules and
cytokines production [7,8]. Moreover, ET-1 has been
shown to be up-regulated in a variety of infectious dis-
eases, such as sepsis [9,10], Chagas' disease [11] or com-
munity acquired pneumonia [12] In contrast, clinical data
on ET-1 in malaria is limited. It has been shown that big
ET-1, a 38-amino acid precursor of ET-1, is elevated in
patients with falciparum malaria [13]. Further, experi-
mental in vivo data indicate that C57Bl/6 mice infected
with  Plasmodium berghei ANKA showed markedly
increased ET-1 mRNA expression [14].
However, co-culture of microvascular endothelial cells
treated with P. falciparum parasitized red blood cells
(pRBC), but not with uninfected red blood cells (RBC),
induced a dose-dependent decrease of ET-1 production
[15]. Interactions of endothelins and natriuretic peptides
are well described in the literature. CNP is a 22-amino
acid peptide that is likely to act as an autocrine or para-
crine agent in the CNP-synthesizing tissues, mainly
endothelial cells [16]. Unlike the other two members of
the Natriuretic Peptide family, the atrial natriuretic pep-
tide (ANP) and the brain natriuretic peptide (BNP), CNP
does not have direct natriuretic activity. CNP has been
found to be a novel endothelium-derived hyperpolarizing
factor that complements the actions of other endothelial
vasorelaxant mediators such as NO and prostacyclin [17].
Scotland et al demonstrated that CNP furthermore inhib-
its leukocyte recruitment and platelet-leukocyte interac-
tions via suppression of P-selectin expression in human
umbilical vein endothelial cells [18]. CNP has not been
investigated in malaria so far and the role of ET-1 in
human falciparum malaria remains unclear. The current
study investigates the levels of ET-1 and CNP in the
plasma of children with severe and uncomplicated
malaria in comparison to healthy controls.
Methods
Study site and participants
All children were consecutively recruited in the paediatric
ward of either the Albert Schweitzer Hospital or the
Regional Hospital of Lambaréné/Gabon between October
2005 and May 2006. The area is hyperendemic for P. fal-
ciparum with transmission year-round [19,20]. The 114
children enrolled in the study were both sexes and aged
between eight months and seven years. 89 malaria cases
and 25 healthy controls (see Table 1) were included. All
groups were sex and age matched. All patients and control
subjects were included in the study only after signed,
informed, parental consent was obtained. The study was
approved by the ethics committee of the International
Foundation of the Albert Schweitzer Hospital in Lam-
baréné, Gabon.
Clinical definition of malaria and study groups
Malaria was defined as a positive blood smear for P. falci-
parum  and presence of fever (axillary temperature ≥
37.5°C or rectal temperature ≥ 38°C) or previous epi-
sodes of fever before admission (assessed by parents or
guardian) in a child presenting with signs and symptoms
of severe or uncomplicated malaria [21]. Severe malaria
(SM) was defined according to the WHO criteria (2000
[21]), including hyperparasitaemia (>10% parasitized red
blood cells), severe anaemia (haemoglobin <5 g/dL),
prostration (inability to sit or in smaller children to drink
unaided), jaundice (clinically assessed by examination of
conjunctiva and palm of hand or if assessable bilirubin >
3 mg%) or respiratory distress (RD, presence of abnormal
deep breathing with nasal flaring, and chest recession).
Children with ≥ one convulsion within 24 hours before
admission and a Blantyre Coma Score (BCS) of ≤ 2 on
admission and no other apparent cause of coma were clas-
sified as cerebral malaria. Age-matched children without
signs and symptoms of infections at time of investigation
and a negative peripheral blood smear for malarial para-
sites served as healthy controls (HC).
Blood collection and physical examination
Venous blood samples were collected, on admission
before starting treatment and 24 hours after admission,
using sterile Sarstaedt S-Monovette citrate plasma tubes
containing 0.106 molar citrate. Plasma was obtained by
centrifugation at 3,000 rcf for 10 min within 30 min of
blood collection and it was stored at -80°C until use. The
physical examination on admission was conducted by theMalaria Journal 2008, 7:253 http://www.malariajournal.com/content/7/1/253
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same investigator and the clinical course of patients was
reported until discharge. In the course of the physical
examination on admission the simplified Multi-Organ-
Dysfunction-Score (sMODS) was performed [22,23],
assessing clinical parameters of disease severity in 10 dif-
ferent organ systems.
Management of patients
According to local guidelines, patients with SM were
treated with intravenous quinine or sulphadoxine-
pyrimethamine in case of uncomplicated malaria.
Laboratory analysis
White and red blood cell counts, haemoglobin (Hb) lev-
els and platelets were determined using an automated
haematology analyzer. Parasitological analysis and assess-
ment of parasitaemia was done according to the Lam-
baréné method [24]. Thick blood films were Giemsa
stained and examined by two different experienced micro-
scopists. Slides were considered to be negative if parasites
were not detected after examination of 100 oil-immersion
fields of the thick smear.
ET-1 and NT-proCNP assays
Plasma concentrations of ET-1 and NT-proCNP were
measured using commercial enzyme-linked immuno-
sorbent assays (ELISA) (BI-20052 and BI-20872, Biomed-
ica Group, Vienna, Austria) in accordance with the
manufacturer's instructions. Natriuretic peptides are pro-
duced as propeptides, which are subsequentially cleaved
to the biologically active, C-terminal hormone and the N-
terminal fragment (NT-proCNP). The N-terminal frag-
ments are more stable, they are easier and more reliable to
be measured in plasma, therefore we decided to use the
sandwich immunoassay for NT-proCNP.
Statistical analysis
In order to reach equal variance and normal distribution,
data of ET-1 and CNP plasma levels were logarithmically
transformed. Levels of ET-1 and CNP were compared
between the groups of interest using one-way ANOVA. P-
values for post-hoc analysis were Bonferroni corrected.
Additionally, non-transformed ET-1 and CNP plasma lev-
els were tested by non-parametrical tests – Kruskal-Wallis
Test and Dunn's post test for multiple comparisons
between groups of interest and Wilcoxon rank sum test
when only two groups were compared. As no difference in
significances was found between parametrical and non-
parametrical tests, results are shown for parametrical test-
ing. Repeated measures of ET-1 and CNP levels were ana-
lysed by paired Students-t test. For non-normally
distributed data Kruskal-Wallis Test and Wilcoxon rank
sum test (when only two groups were compared), were
used respectively. Proportions were analysed by Chi-
square test. Correlations between different variables were
analysed by Pearson correlation and Spearman's rank
respectively depending on the distribution of the data.
Statistical significance was defined as two-sided p-value <
Table 1: Demographic, clinical, and laboratory characteristics of study groups
Characteristics Study groups
SM UM p Value HC
Number of subjects 50 39 25
Gender female/male 20/30 23/16 NS× 14/11
+Age (months) 30 (9–86) 35 (9–83.5) NS‡ 31.5 (10–77)
+Onset of signs and symptoms in days before admission 3 (0–30) 3 (0–21) NS
+sMODS 18 (13–26) 13 (10–20) < 0.001
+Parasite count (μL-1) 69,225 (155–900,000) 23,910 (425–180,000) < 0.05
WBC × 103 (μL-1) 10.5 ± 5.9 7.7 ± 3.1 < 0.05 8.9 ± 2.6
RBC × 106 (μl-1) 2.9 ± 1.1 3.8 ± 0.6 < 0.001 4.7 ± 0.5
Mean Hb (g/dL) 6.8 ± 2.5 8.7 ± 1.5 < 0.001 10.7 ± 1.0
Platelets × 103 (μl-1) 159 ± 109 220 ± 132 < 0.005 381 ± 98
ET-1 on admission (fmol/ml) 0.76 ± 0.48 1.11 ± 0.98 <0.001‡ 0.49 ± 0.31
ET-1 after 24 hours (fmol/ml) 0.72 ± 0.49 0.95 ± 0.71 NS‡
CNP on admission (pmol/l) 11.05 ± 6.58 11.49 ± 4.55 <0.05‡ 14.29 ± 6.4
CNP after 24 hours (pmol/l) 11.5 ± 6.83 9.92 ± 3.64 NS‡
Data are mean (standard deviation), unless otherwise indicated. +Median (interquartile range). Wilcoxon rank sum test was used for testing of 
statistical significance unless not otherwise indicated. ×Chi-Square test; ‡ANOVA. NS: not significant. SM: severe malaria; UM: uncomplicated 
malaria; HC healthy control; sMODS: simplified Multi-Organ-Dysfunction-Score; RBC: red blood cells; Hb: haemoglobin; WBC: white blood cells.Malaria Journal 2008, 7:253 http://www.malariajournal.com/content/7/1/253
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0.05. Calculations were done using SPSS 15 (Insightful
Corporation, Chicago, USA), graphs were drawn by
GraphPad Prism version 5.00 (GraphPad Software, San
Diego, USA).
Results
Characteristics of study population
Eighty-nine children with P. falciparum malaria were
enrolled in the study, which had SM (n = 50) or UM (n =
39). Twenty-five children served as HC (n = 25). Demo-
graphic, clinical, and laboratory characteristics of the
study groups are summarized in Table 1. Out of 50
patients with SM, 20 had severe anaemia (40%), 26
patients (52%) had one or more convulsions within the
last 24 hours before admission and six patients (12%)
showed hyperparasitaemia. Thirty-two children (64%)
were prostrated, 20 had impaired consciousness (40%),
25 showed jaundice (50%) and 23 had respiratory distress
(46%). Seven children (14%) fulfilled WHO criteria to be
classified as CM. The sMODS was significantly higher in
SM than in UM (p < 0.001).
Plasma levels of ET-1 and NT-proCNP
ET-1 serum levels were significantly higher in all malaria
patients compared with HC on admission (p < 0.001) and
after 24 hours of treatment (p = 0.018). On admission UM
patients showed significantly higher levels when com-
pared to HC (p < 0.001) and a trend towards higher levels
(p = 0.085) than SM patients. SM patients also had signif-
icantly higher ET-1 levels than HC (p = 0.029). After 24
hours of treatment, UM patients still showed significantly
higher ET-1 levels when compared with HC (p = 0.019),
but a significant difference was seen neither between SM
and HC (p = 0.249) nor SM and UM (p = 0.474) patients
(Figure 1).
On admission, all malaria patients showed lower CNP
levels compared to HC (p = 0.024). SM patients had sig-
nificantly lower NT-proCNP levels than HC (p = 0.034),
but levels of UM patients were not statistically different to
those from HC (p = 0.254). After 24 hours of treatment,
all malaria patients showed lower levels compared to HC
(p = 0.009). NT-proCNP plasma levels of UM patients
were significantly lower than HC (p = 0.043) and SM still
showed a trend towards lower NT-proCNP levels com-
pared to HC (p = 0.069). Neither on admission nor after
24 hours of treatment was any significant difference seen
between UM and SM (Figure 2).
Clinical correlations with ET-1 plasma levels
Children with severe anaemia within the SM group
yielded significantly lower ET-1 levels on admission (p =
0.041).
Discussion
In this study, it is shown that ET-1 is significantly higher
and CNP significantly lower in P. falciparum malaria com-
pared to healthy controls, i.e. opposed plasma levels of
ET-1 and CNP.
A key feature of P. falciparum malaria pathogenesis is the
activation of the vascular endothelium due to – amongst
others – the production of pro-inflammatory mediators
such as cytokines and chemokines, resulting in up-regula-
tion of adhesion molecules and sequestration of pRBCs,
mononuclear leukocytes and platelets [25,26]. Both ET-1
and CNP are produced mainly by vascular endothelium
and act locally as paracrine regulators of vascular tone
[6,27]. Pathways of CNP and ET-1 synthesis from pro-
CNP and pro-ET-1, respectively, are similar as they both
require furin-mediated processing of precursors [28,29].
However, ET-1 is a potent vasoconstrictor [6] whereas
CNP has strong vasorelaxant properties [17].
These findings correspond well with elevated plasma lev-
els of big ET-1 found in patients with complicated malaria
by Wenisch et al [13]. Furthermore, it has been shown that
expression of several components of the endothelin path-
way including ET-1, endothelin converting enzyme
(ECE), and the endothelin receptors A and B (ETA and
Endothelin-1 plasma levels Figure 1
Endothelin-1 plasma levels. Circulating plasma levels of 
endothelin-1 (ET-1) in children with severe malaria (SM, 
square dots), uncomplicated malaria (UM, triangle dots) on 
admission to hospital and after 24 hours of treatment and 
healthy controls (HC, round dots), determined using ELISA-
technique. Scatter plots, lines indicate Median values. Analy-
ses by ANOVA, p-values were Bonferroni corrected for mul-
tiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001Malaria Journal 2008, 7:253 http://www.malariajournal.com/content/7/1/253
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ETB) are markedly increased in mice with cerebral malaria
[14]. Basilico et al investigated the production of ET-1 by
human microvascular endothelial cells (HMEC) and
human umbilical vein endothelial cells (HUVEC), co-cul-
tured with pRBCs. ET-1 production in both HMEC-1 and
HUVEC was increased by hypoxia and Interleukin 1 beta
(IL1-beta). However, both normoxic ET-1 production as
well as hypoxia- or IL1-beta-induced ET-1 production was
reduced in a dose-dependent manner by co-incubation
with pRBCs, but not with uninfected RBCs [30,31].
The results of this study demonstrate a trend towards
lower ET-1 levels in SM compared to UM. As circulating
pRBCs do not reflect the degree of endothelial cell activa-
tion and pRBC sequestration in the microvasculature, the
decreasing ET-1 levels in SM patients could indirectly rep-
resent inhibition of endothelial ET-1 production by
sequestered pRBCs, as demonstrated in vitro by Basilico et
al [15]. This might be the reason for the lack of correlation
between parasitaemia, ET-1 levels and clinical disease
severity. Another reason for the observed trend towards
lower ET-1 levels together with significantly lower CNP
levels in SM patients could be endothelial cell damage
during SM. Pro-inflammatory up-regulation of adhesion
molecules with intense sequestration could provoke sub-
sequent cell damage with either inhibition or inability to
increase the production of endothelial substances such as
ET-1 or CNP in SM. Endothelial cell damage and its
impact on the clinical course of malaria is not yet clear.
However, in vitro studies as well as murine experiments
indicate important vulnerability of endothelial cells dur-
ing severe/cerebral malaria [31,32].
The current findings demonstrate an imbalance between
vasoconstricitve and vasorelaxant endothelium-derived
substances, circulating in children with falciparum
malaria. The preponderance of vasoconstrictive effects
may not only be due to elevated ET-1 and decreased CNP
levels, but also indirectly via impaired endothelial nitric
oxide (NO) production, one of the main endothelium-
derived relaxing factors. Razmy et al were able to establish
a link between ET-1 and NO production, which was
decreased in human saphenous vein endothelial cells
after exposure to ET-1 [33]. NO has host protective and
anti-inflammatory roles (reviewed in [34]) and its func-
tions have been studied extensively in malaria (reviewed
in [2,33-37]). Gramaglia et al could recently show that
low NO bioavailability contributes to the genesis of
murine cerebral malaria and mice treated with exogenous
NO did not develop severe malaria [38]. Similar to NO,
CNP may exhibit not only vasodilatory but also anti-
inflammatory actions in the vasculature. Scotland et al
demonstrated that CNP modulates leukocyte-endothelial
interactions by down-regulating P-selectin expression
directly suppressing leukocyte recruitment. In addition,
platelet aggregation and platelet-leukocyte interactions
were inhibited by a CNP-mediated suppression of P-selec-
tin expression on platelets indicating an antithrombotic
role of CNP [17,18]. As upregulation of adhesion mole-
cules, activation and sequestration of platelets, leuko-
cytes, pRBCs and RBCs are important features of SM
pathogenesis [2,25,39], the findings of low CNP levels in
the SM group could be interpreted as an insufficient coun-
terregulatory CNP upregulation – with its possible protec-
tive anti-inflammatory and vasodilatory effects –
probably due to endothelial damage as mentioned above.
Similarly to these findings of low CNP levels in SM we had
already described significantly lower levels of tissue inhib-
itor of matrix metalloproteinases-2 (TIMP-2) in the same
cohort of patients [40].
However, it has to be considered that plasma levels do not
truly reflect the microvascular situation at the site of
inflammation. Said et al described increased ET-1 levels
which were more pronounced in mucosal tissue than in
plasma in a rat model of stress-induced mucosal haemor-
rhage [41]. ET-1 and CNP may act in a paracrine fashion,
therefore a correlation between circulating plasma ET-1
NT-proCNP plasma levels Figure 2
NT-proCNP plasma levels. Circulating plasma levels NT-
pro C-type natriuretic peptide (CNP) in children with severe 
malaria (SM, square dots), uncomplicated malaria (UM, trian-
gle dots) on admission to hospital and after 24 hours of 
treatment and healthy controls (HC, round dots), deter-
mined using ELISA-technique. Scatter plots, lines indicate 
Median values. Analyses by ANOVA, p-values were Bonfer-
roni corrected for multiple comparisons. *p < 0.05, **p < 
0.01, ***p < 0.001Malaria Journal 2008, 7:253 http://www.malariajournal.com/content/7/1/253
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and CNP concentration and disease severity might not
directly reflect the pathogenetic importance of ET-1 and
CNP in severe malaria.
A possible interaction of treatment with plasma levels of
ET-1 may also be taken into consideration. An inhibitory
effect on ET-1 production in HUVECs has been shown for
substances such as ursodeoxycholic acid [42]. Del Pozo et
al described a downward shift of contractions of isolated
thoracic aortic rings induced by endothelin-1 in response
to a pretreatment with high concentrations of quinine
[43]. All the studied patients with severe malaria were
treated with intravenous quinine, according to local
guidelines. Whether schizonticidal therapy, such as qui-
nine, and host-derived endothelial peptides, such as ET-1
and CNP, may interact at a circulating enzyme level or
could be more pronounced at receptor levels is still insuf-
ficiently investigated and, therefore, poses an important
research challenge.
Conclusion
The pathophysiological significance of ET-1 and CNP in
malaria is still an open-ended question. Many factors con-
tribute to the course of malaria (eg, pro-inflammatory
mediators, sequestration, endothelial activation), thus, it
is difficult to assess the contributory role of two specific
factors. However, the results of this study provide evi-
dence for an involvement of substances produced in the
endothelium in SM pathogenesis and underline the
importance of further investigation of the vascular com-
partment, in particular endothelial cells, and their contri-
bution to the development of the devastating multi-organ
complications defining severe malaria.
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